GERD Infant Feeding Therapeutics Trial (GIFT Trial)

Last updated: October 3, 2024
Sponsor: Nationwide Children's Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Esophageal Disorders

Gastroesophageal Reflux Disease (Gerd)

Heartburn (Pediatric)

Treatment

AR formula

Omeprazole

Clinical Study ID

NCT06114836
STUDY00003300
1R01DK136762-01
  • Ages 1-8
  • All Genders

Study Summary

The goal of this investigator-initiated, single-center, randomized controlled trial (RCT) is to compare the effects of four weeks of three therapies on clinical and mechanistic outcomes based on pH-Imp testing using a three-arm parallel design in NICU infants with objective GERD diagnosis. The three therapies being compared are natural maturation, proton pump inhibitor (PPI) use, and added rice (AR) formula use. The main goals are:

  • to evaluate and compare the efficacy of the three commonly used treatment interventions used in the NICU for GERD in a randomized controlled manner with the primary endpoint of oral feeding success and absence of troublesome symptoms (as defined below).

  • to characterize the mechanisms of primary end point (success or failure) using pH-Impedance metrics.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • NICU infants of any gestational age who are between 37 - 47 weeks postmenstrual ageat inception of the study meeting the following requirements:

  • GERD diagnosis using pH-impedance criteria (Acid Reflux Index ≥ 3% plus atleast one of the following: # GER events >70 / day, Symptom AssociatedProbability ≥ 95%, Discal Baseline Impedance < 900 Ω)

  • Full enteral feeds

  • No current GERD therapies

Exclusion

Exclusion Criteria:

  • Known lethal chromosomal abnormalities or complex congenital syndromes

  • Severe neurologic pathologies requiring neuroactive medications or neurosurgery

  • Positive airway pressure or oxygen flow > 4 LPM

  • Upper gastrointestinal malformations requiring surgery

Study Design

Total Participants: 369
Treatment Group(s): 2
Primary Treatment: AR formula
Phase:
Study Start date:
March 14, 2024
Estimated Completion Date:
November 30, 2028

Study Description

In consented subjects, eligibility is determined after initial diagnostic 24-hour pH Impedance test. These subjects will be randomized to one of the 3 arms of the study (natural maturation, PPI, AR formula) for 4 weeks of treatment. A second 24-hour pH Impedance test will be done on therapy at 4 weeks or before discharge, whichever occurs first. Primary outcome will also be measured at 4 weeks or at discharge, whichever comes first.

Connect with a study center

  • Nationwide Children's Hospita

    Columbus, Ohio 43215
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.